Darglitazone

Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.^[1]

Darglitazone

Legal status
Legal status	Development terminated
Identifiers
IUPAC name 5-[(4-[3-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl)methyl]-1,3-thiazolidine-2,4-dione
CAS Number	141200-24-0 Y
PubChem CID	60870
ChemSpider	54854 N
UNII	AVP9C03Z3K
ChEMBL	ChEMBL55624 N
CompTox Dashboard (EPA)	DTXSID3057644
Chemical and physical data
Formula	C23H20N2O4S
Molar mass	420.48 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)NC(=O)S4
InChI InChI=1S/C23H20N2O4S/c1-14-18(24-22(29-14)17-5-3-2-4-6-17)11-12-19(26)16-9-7-15(8-10-16)13-20-21(27)25-23(28)30-20/h2-10,20H,11-13H2,1H3,(H,25,27,28) N Key:QQKNSPHAFATFNQ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Its development was terminated on November 08, 1999.^[2]

Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production. It's an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), a transcription factor. Darglitazone can increase the effectiveness of insulin in people with obesity and type 2 diabetes. Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production.

Synthesis

Synthesis of darglitazone